Who Optimizes SG&A Costs Better? Viatris Inc. or Amneal Pharmaceuticals, Inc.

Optimizing SG&A Costs: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Viatris Inc. and Amneal Pharmaceuticals, Inc. have shown contrasting strategies in this area. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, Amneal Pharmaceuticals, Inc. maintained a more conservative approach, with expenses reaching around $430 million in the same year. This disparity highlights Viatris's expansive operational strategy compared to Amneal's more streamlined approach. Despite Viatris's expenses being nearly ten times higher, both companies have navigated the pharmaceutical landscape with unique strategies. Understanding these differences provides valuable insights into how each company positions itself in the market, balancing growth and cost efficiency.

Short Description

"SG&A Cost Strategies: Viatris vs. Amneal - A Decade of Insights"